Ånds

1,291 views

Published on

Published in: Health & Medicine, Education
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,291
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
3
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Ånds

  1. 1. CURRICULUM VITAE PART I: GENERAL INFORMATION Date Prepared: February 1, 2005 Name: Perry Franklin Renshaw Office Address: McLean Hospital, 115 Mill Street, Belmont, MA 02478 E-Mail: perry@mclean.harvard.edu Fax: 617-855-2770 Place of Birth: Oakland, California, U.S.A. Education: 1982 S.B. Massachusetts Institute of Technology 1987 Ph.D. University of Pennsylvania (Biophysics) 1988 M.D. University of Pennsylvania Postdoctoral Training: Internships and Residencies: 1988-1989 Intern in Medicine, Brigham and Women's Hospital, Boston, MA 1989-1992 Resident in Psychiatry, Massachusetts General Hospital, Boston, MA Clinical and Research Fellowships: 1986-1988 Postdoctoral Research Associate, Metabolic NMR Research Resource, University of Pennsylvania, Philadelphia, PA 1988-1989 Clinical Fellow in Medicine, Harvard Medical School, Boston, MA 1989-1992 Clinical Fellow in Psychiatry, Harvard Medical School, Boston, MA 1991-1992 Psychiatric Neuroscience Fellow, Massachusetts General Hospital, Boston, MA Licensure and Certification: 1991 Massachusetts License Registration #73551 1993 American Board of Psychiatry and Neurology, Certificate #38398 Academic Appointments: 1992-1993 Instructor in Psychiatry, Harvard Medical School 1994-1997 Assistant Professor of Psychiatry, Harvard Medical School 1997- 2003 Associate Professor of Psychiatry, Harvard Medical School 2001- Adjunct Associate Professor of Psychiatry, Boston University School of Medicine 2003 - Professor of Psychiatry, Harvard Medical School Hospital or Affiliated Institution Appointments: 1992-1994 Assistant Psychiatrist, McLean Hospital, Belmont, MA 1992-1994 Consultant in Radiology, Massachusetts General Hospital, Boston, MA
  2. 2. Curriculum Vitae Perry Franklin Renshaw 1992- Clinical Assistant in Psychiatry, Massachusetts General Hospital, Boston, MA 1993-1999 Visiting Scientist, Clinical Research Center, Massachusetts Institute of Technology, Cambridge, MA 1994-1997 Associate Psychiatrist, McLean Hospital, Belmont, MA 1997- Psychiatrist, McLean Hospital, Belmont, MA 2004- Consultant, Psychiatric Service, Massachusetts General Hospital, Boston, MA Hospital Principal Clinical and Service Responsibilities: 1992-1997 Research Director, Brain Imaging Center, McLean Hospital, Belmont, MA 1994- Assistant Director, Brain Imaging Center, McLean Hospital, Belmont, MA 1995-1997 Associate Director, Brain Imaging Center, McLean Hospital, Belmont, MA 1997- Director, Brain Imaging Center, McLean Hospital, Belmont, MA Major Committee Assignments: Regional 1999 Steering Committee, Commonwealth Research Center of Excellence 1999 External Advisory Committee, Center for Advanced Brain Imaging, Nathan S. Kline Institute for Psychiatric Research National 1995 Special Review Committee, National Institute on Drug Abuse 1995 Chairman, Subcommittee on Recruitment, International Society of Magnetic Resonance in Medicine 1996-1998 Behavioral Science Initial Review Group, National Institute on Drug Abuse 1997 Center Grant Review Committee, National Institute on Alcoholism and Alcohol Abuse 1997-2000 VA Merit Review Subcommittee for Mental Health and Behavioral Sciences 1998 Brain Disorders and Clinical Neuroscience 6 IRG, Center for Scientific Review 1998 NIMH Intramural Clinical Research Planning Panel 1998-2002 National Advisory Council on Drug Abuse, NIH 2000 Center Grant Review Committee, National Institute on Alcoholism and Alcohol Abuse 2000 Strategic Planning Committee, Medications Development Division, National Institute on Drug Abuse 1999.2003 Scientific Program Committee, College on Problems of Drug Dependence 2003- Scientific Program Committee, Society of Biological Psychiatry 2004- Scientific Program Committee, American College of Neuropsychopharmacology Memberships in Professional Societies: 1986- International Society of Magnetic Resonance in Medicine 1990- American Psychiatric Association 1992- Society of Biological Psychiatry 1995- Society for Neuroscience 1997- College on Problems of Drug Dependence 2000- American College of Neuropsychopharmacology 2005- International Society for CNS Clinical Trials & Methodology Editorial Boards: 1996- Psychiatry Research: Neuroimaging 1998- Bipolar Disorders 2001 - Biological Psychiatry 2
  3. 3. Curriculum Vitae Perry Franklin Renshaw Ad Hoc Reviewer: Alzheimer’s Disease and Related Disorders American Journal of Psychiatry Archives of General Psychiatry Biological Psychiatry Cerebral Cortex Journal of the American Medical Association Magnetic Resonance Imaging Magnetic Resonance in Medicine Neuropsychopharmacology Schizophrenia Research Awards and Honors: 1981 Atlantic Richfield Prize, MIT 1981 Pi Lambda Upsilon 1982 Alpha Chi Sigma Prize, Department of Chemistry, MIT 1982 Phi Beta Kappa, MIT 1982 Sigma XI 1982 NIH Medical Scientist Training Program Fellowship 1987 Alpha Omega Alpha 1988 Kenneth E. Appel Award, University of Pennsylvania 1988 Dr. Edward J. Sachar Prize, University of Pennsylvania 1988 Dr. Robert M. Toll Prize, University of Pennsylvania 1990 NIMH Outstanding Resident Award 1992 Livingston Fund Award, Harvard Medical School 1992 Ethel Dupont-Warren Fellowship Award, Harvard Medical School 1992 American College of Neuropsychopharmacology Travel Award 1993 NARSAD Young Investigator Award 1995 International Congress on Schizophrenia Research Young Investigator Award 1995 Alfred Pope Award, McLean Hospital 1995 NARSAD Young Investigator Award 1996 Award for Excellence, Partner's Healthcare, Inc. 1997 APA/Smith Kline Beecham Young Faculty Award 1997 Member, American College of Neuropsychopharmacology 1999 Pfizer Visiting Professor, Mount Sinai School of Medicine 1999 Pharmacopsychiatry Section Prize, World Psychiatric Association 2000 NARSAD Independent Investigator Award 2001 Pfizer Visiting Professor, University of Mississippi, College of Medicine 2001 Gerald L. Klerman Award for Clinical Research, NARSAD PART II: RESEARCH, TEACHING AND CLINICAL CONTRIBUTIONS A. Narrative Report: An important strength of magnetic resonance methods for clinical research arises from the fact the technique is non-invasive and repeated assessments of brain anatomy, chemistry, and function in individual subjects are entirely feasible. However, a serious limitation of this technology, relative to emission tomography, is the modest sensitivity of the method. For example, PET studies are quite capable of measuring the occupancy of cell surface receptors with a concentration on the order of 100 nanomolar. In contrast, the lowest concentration of a neuro-chemical that has been detected at 1.5 T in humans is on the order of 1-2 micromolar (Christensen et al. 1998, 1999; Henry et al., 2000). Thus, the aim of detecting either acute or chronic effects of drugs on the human brain using MRS, and the more 3
  4. 4. Curriculum Vitae Perry Franklin Renshaw recently developed functional magnetic resonance imaging (fMRI), presents a satisfying challenge. Research studies have included both the development of new methods for making measurements (e.g. Levin et al., 1995; Keltner et al., 1996, 1997; Maas et al., 1997, 1999) as well as their application in clinical populations (Streeter et al.,1998 ; Kaufman et al., 1998; Maas et al., 1998; Teicher et al., 2000 ). As we began to publish our study results, I was approached by a growing number of students, fellows, and colleagues who were interested in learning how to apply these methods in their own research. Indeed, between 1994 and 2000, I supervised a number of fellows, including nine psychiatrists, one neurologist, one neuroscientist, one pharmacologist, six physicists, and three MIT graduate students in Biomedical Engineering. As many of the trainees who find their way to McLean Hospital are very talented, this opportunity to continue my teaching endeavors was very satisfying, and I am especially heartened by the number of former fellows who have now become my colleagues. Over the last decade, there has been a tremendous expansion of my administrative responsibilities. The former Director of the Brain Imaging Center at McLean Hospital resigned unexpectedly in 1993, one year after I assumed my position. Following his departure, I acquired responsibility for all aspects of the operation of the Brain Imaging Center. Driven largely by the success of our research program, the Center grew dramatically. In 1992, the full time staff of the McLean Brain Imaging Center included a total of 7 full time employees who supported both clinical and research activities. Our initial research budget was funded with extramural grants of approximately $50,000. At the end of 2000, our staff included 53 full time employees and our extramural funding for the Brain Imaging Center was approximately 4 million dollars/year. An important aspect of clinical neuroimaging research is that it is not a mature discipline and there are a number of ongoing technical advances. In magnetic resonance research, one of the important new developments is the availability of high field (3, 4, and 7 T) scanners for human studies. In order to keep our facilities current, I wrote a National Center for Research Resources Shared Instrumentation Grant application (S10 RR13938) and a proposal to the Office of National Drug Control Policy (DABT63-99-C-0044) to support the purchase of a new 4 T scanner for the McLean Brain Imaging Center. Both of these proposals were funded. A new 20,000 square foot Brain Imaging Center, housing a new 1.5 T General Electric Signa and 4.0 T Varian Unity/Inova scanners were dedicated on May 15, 2001. This unique research facility will be fully dedicated to magnetic resonance research, at least half of which will involve substance abuse studies. B. Research Funding Information: Past 1992-1993 Livingston Fund, Harvard Medical School PI Brain MRI in children with ADHD. 1992 Digital Equipment Corporation Co-PI Multimodal brain imaging in Alzheimer's disease. 1993 MIT Clinical Research Center Co-PI Changes in brain choline uptake with age. 1993-1994 Hood Foundation PI Morphometric brain MRI in normal children. 1993-1994 General Electric Medical Systems PI Proton MRS in major depression. 1994 Polaroid Foundation PI High resolution functional imaging. 4
  5. 5. Curriculum Vitae Perry Franklin Renshaw 1994 Bracco Diagnostics PI Cerebral blood volume mapping in patients with neuropsychiatric disorders. 1993-1995 John W. Alden Trust PI Morphometric brain MRI in children with ADHD. 1993-1995 Scottish Rite Schizophrenia Program Co-PI Cognitive challenge using echo-planar MRI. 1993-1995 NARSAD Young Investigator Award PI Multinuclear MRS in first episode psychosis. 1993-1995 Stanley Foundation PI Multinuclear MRS in major depression. 1993-1995 Advanced NMR Systems, Inc. PI Application of echo-planar imaging to the study of mental illness. 1994-1995 Interneuron Pharmaceuticals, Inc. Co-PI Proton MRS studies on the effects of CDP-choline in brain in vivo. 1994-1995 Interneuron Pharmaceuticals, Inc. Co-PI Measurement of brain dexfenfluramine levels in man by 19F MRS. 1994-1995 ADRDA Pilot Grant PI Concurrent measurement of brain structure and function in Alzheimer’s Disease. 1995 Invivo Research Inc. PI Clinical evaluation of nonferrous patient monitoring systems. 1995 Hewlett Packard PI Image processing of echo planar time series data. 1995 Fidelity Foundation Co-PI MR scanner upgrade grant. 1994-1996 Scottish Rite Schizophrenia Program PI Measurement of brain GABA in man by MRS. 1995-1996 Bracco Diagnostics PI Cerebral blood volume mapping in patients with psychotic disorders. 1995-1996 Eli Lilly, Inc. Co-PI fMRI studies of psychotic patients before and after olanzapine treatment. 5
  6. 6. Curriculum Vitae Perry Franklin Renshaw 1996 Digital Equipment Corporation Co-PI Analysis of fMRI time series data. 1995-1997 John W. Alden Trust PI Multimodal brain MR studies of children with ADHD. 1995-1997 Stanley Foundation Co-PI Proton echo planar spectroscopic imaging. 1995-1997 Stanley Foundation Co-PI Frontal lobe structure and function in depressed adolescents. 1996-1997 Eli Lilly, Inc. PI Multinuclear MRSI studies before and after xanomeline treatment. 1997-1998 American Suicide Foundation Co-PI Brain MRI in suicidal and non-suicidal hospitalized children and adolescents. 1997-1998 APA/Smith Kline Beecham PI Phospholipid precursors as therapy for affective illness. 1997-1998 Bracco Diagnostics Co-PI Cerebral blood volume mapping in major depression. 1996-1998 General Electric Medical Systems PI Clinical fMRI studies of schizophrenia and Alzheimer’s disease. 1996-1998 Hood Foundation Co-PI High resolution MRI and fMRI in normal adolescents. 1998 Scios, Inc. Co-PI Brain lithium levels following sustained release lithium and lithium salts. 1997-1998 Eli Lilly, Inc. Co-PI Pharmacokinetics of brain fluoxetine levels. 1996-1998 NARSAD Young Investigator Award PI MRS studies of myo-inositol in affective illness. 1997-1999 Eli Lilly, Inc. Co-PI Proton MRSI studies of brain glutamate before and after olanzapine treatment. 1997-1999 Interneuron Pharmaceuticals PI Phosphorus MRSI studies of human brain phospholipids during CDP-choline therapy. 1997-1999 Stanley Foundation PI 6
  7. 7. Curriculum Vitae Perry Franklin Renshaw Brain lithium and myo-inositol in bipolar disorder. 1998-1999 Smith Kline Beecham Co-PI Pharmacokinetics of brain SSRI levels. 1997-1999 Center for Disease Control Co-Inv Cognitive function and symptom patterns in Gulf War veterans. 1999 National Center for Research Resources PI Shared Instrument Grant for a 4.0 T MR scanner. 1996-2000 National Institute of Mental Health Co-Inv Early abuse and corticolimbic development. 1996-2001 National Institute of Mental Health Co-Inv Frontal lobe structure and function in depressed adolescents. 1998-2001 Veterans Administration - Department of Defense Co-Inv Effects of combat stress on the structure and function of the hippocampus. 1998-2001 Veterans Administration Mentor A functional MRI study of alcohol cue-induced craving and naltrexone 1999-2002 National Institute on Drug Abuse Co-PI Medication development for cocaine abuse: CDP-choline. 1999-2002 National Institute on Alcoholism and Alcohol Abuse Co-Inv Brain alcohol MRS and family history of alcoholism. 1996-2003 Stanley Foundation Bipolar Center Grant Co-Inv MRSI studies of brain chemistry in bipolar disorder. 1998-2003 National Institute on Drug Abuse Site-PI MR spectroscopic imaging during methadone maintenance. 1998-2003 National Institute on Mental Health Co-Inv Collaborative schizophrenia studies. 1998-2003 National Institute on Mental Health Co-Inv Brain choline uptake and late life mental illness. 1999-2003 National Institute of Mental Health PI Proton MRSI studies of bipolar disorder. 1999-2003 Office of National Drug Control Policy PI High field of magnetic resonance scanner for drug abuse research 2000-2003 NARSAD Independent Investigator Award PI Brain purines in major depression 7
  8. 8. Curriculum Vitae Perry Franklin Renshaw 2002.2003Sepracor PI Monitoring drug levels by 19F MRS Current: 2003-2008 National Institute of Mental Health Co-Inv Effects of Emotional Maltreatment on Brain Function 2003-2007 National Institute on Drug Abuse Co-Inv Early Stress and Neural Substrates Relevant to Addiction 2003-2007 National Institute on Drug Abuse Co-Inv Neurochemical Substrates of Sleep Homeostasis 2002-2007 National Institute on Drug Abuse PI Mentoring in Drug Abuse Neuroimaging 2004-2006 Varian PI X-nuclear MRS in Psychiatry 2003-2006 Descartes Pharmaceuticals fMRI in Drug Development PI 2003-2006 Siemens PI Novel MR Methods in Psychiatry 2002-2006 National Institute on Drug Abuse Co-Inv Cocaine and Steroids: Brain Vascular and Behavioral Effects 2002-2006 National Institute of Mental Health Co-Inv Depression and Brain Structure in Type 1 Diabetes 2001-2006 National Institute on Drug Abuse PI High Field MR Research on Drug Abuse: A Bioengineering Partnership 2001-2006 National Institute on Drug Abuse Co-Inv Polydrug Abuse: EEG and Behavior 1996-2005 Stanley Foundation Bipolar Center Grant Co-Inv MRSI studies of brain chemistry in bipolar disorder. 1994-2004 National Institute on Drug Abuse PI Magnetic resonance, EEG, and mood after cocaine. 1996-2004 National Institute on Alcohol Abuse and Alcoholism Co-Inv Isoflavone Treatment for Alcohol Abuse 1998-2004 National Institute on Drug Abuse Site-PI MR spectroscopic imaging during methadone maintenance. 1999-2004 National Institute on Drug Abuse Co-Inv 8
  9. 9. Curriculum Vitae Perry Franklin Renshaw Residual Cognitive Effects on Cannabis: An fMRI Study 2000-2004 National Institute of Mental Health Co-Inv Brain injury in torture survivors: A mental health impact 2003-2004 GlaxoSmithKline PI MR Studies of Treatment-Induced Edema 2003-2004 GlaxoSmithKline PI 2D MRS Studies of Brain Amino Acids C. Current Research Activities: 2003.2008 National Institute of Mental Health Co-Inv Effects of Emotional Maltreatment on Brain Function 2003-2007 National Institute on Drug Abuse Co-Inv Early Stress and Neural Substrates Relevant to Addiction 2003-2007 National Institute on Drug Abuse Co-Inv Neurochemical Substrates of Sleep Homeostasis 2002-2007 National Institute on Drug Abuse PI Mentoring in Drug Abuse Neuroimaging 2003-2006 Descartes Pharmaceuticals PI fMRI in Drug Development 2003-2006 Siemens PI Novel MR Methods in Psychiatry 2002-2006 National Institute on Drug Abuse Co-Inv Cocaine and Steroids: Brain Vascular and Behavioral Effects 2002-2006 National Institute of Mental Health Co-Inv Depression and Brain Structure in Type 1 Diabetes 2001-2006 National Institute on Drug Abuse PI High Field MR Research on Drug Abuse: Bioengineering Partnership 1994-2004 National Institute of Drug Abuse PI Magnetic resonance, EEG, and mood after cocaine. 1996-2004 National Institute on Alcohol Abuse and Alcoholism Co-Inv Isoflavone Treatment for Alcohol Abuse 1999-2004 National Institute on Drug Abuse Co-Inv Residual Cognitive Effects on Cannabis: An fMRI Study 1999-2004 Hood Foundation Co-Inv Longitudinal fMRI studies of normal adolescents. 2000-2004 National Institute of Mental Health Co-Inv 9
  10. 10. Curriculum Vitae Perry Franklin Renshaw Brain injury in torture survivors: A mental health impact 2002-2004 Joslin Diabetes Center PI Depression & Brain Structure in Type 1 Diabetes 2003-2004 GlaxoSmithKline PI MR Studies of Treatment-Induced Edema 2003-2004 GlaxoSmithKline PI 2D MRS Studies of Brain Amino Acids D. Report of Teaching: 1. Local Contributions: 1991- Lecturer on neuroimaging for psychiatry residents and neuroscience fellows at the Massachusetts General Hospital, McLean Hospital, the Beth Israel Hospital and Children's Hospital. 5-10 residents/session 6-10 hours/year 1991- Lecturer on neuroimaging in psychiatry for Continuing Medical Education courses at the Massachusetts General Hospital and McLean Hospital. 20-120 attendees/session 4-6 hours/year 1996-1998 Lecturer on neuroimaging for Boston University School of Medicine students. 20 students/session 10 hours/year Advisees and Trainees 1. James D. Christensen, Ph.D. Post-doctoral fellow (physics), 1993-1994. NARSAD Young Investigator, 1994-1996. Assistant Professor of Psychiatry and Radiology, University of Texas, Southwestern, 1996-1999. Assistant Professor in Psychiatry and Radiology, University of Louisville, Louisville, KY, 1999-present. 2. John R. Keltner, Ph.D. Post-doctoral fellow (physics) 1994-1996. Scottish Rite Schizophrenia Research Grant, 1993-1995. M.D., Harvard Medical School, 1997. Intern in Internal Medicine, Mount Auburn Hospital, 1998-1999. Residency in Anesthesiology, University of California, San Francisco, CA, 1999-2002. Instructor in Anesthesiology, University of California, San Francisco, CA 2002-present. 3. Beny Lafer, M.D. Clinical Neuroscience Fellow, 1994-1995. Director, Mood Disorders Clinic University of Sao Paolo, Brazil, 1995-present. Associate Professor of Psychiatry, Sao Paolo, Brazil, 1998-present. 4. James Selph, M.S., Master’s Thesis, 1995. Biomedical Engineering Program, Massachusetts Institute of Technology, Cambridge, MA. 5. In Kyoon Lyoo, M.D. Post-doctoral fellow (psychiatric neuroimaging), 1993-1995. Instructor in Psychiatry, Seoul National University, 1996. Assistant Professor in Psychiatry, Seoul National University, 1997-present. NARSAD Young Investigator, 2000-2002. Clinical Investigator 10
  11. 11. Curriculum Vitae Perry Franklin Renshaw Training Program Fellowship, MIT/Harvard Medical School, 2000-2002, Instructor in Psychiatry, Harvard Medical School, Boston, MA, 2000-present. Associate Professor of Psychiatry, Seoul National University, School of Medicine, 2003-present. 6. Blaise deB. Frederick, Ph.D. Post-doctoral fellow (physics) 1995-1997. Stanley Foundation Research Grant, 1995-1997. Assistant Professor in Psychiatry, Harvard Medical School, 2002 - present. Whitaker Foundation Biomedical Engineering Grant, 1997-1999. NIDA Mentored Quantitative Scientist Development Award, 2001-2006. Assistant Professor of Psychiatry, Harvard Medical School, 2002-present. 7. Jonathan M. Levin, M.D. Post-doctoral fellow (functional neuroimaging) 1994-1995. Finalist, Society of Magnetic Resonance Young Investigator Award, 1995. Instructor in Neurology, Harvard Medical School, 1995-1998. National Institute on Drug Abuse Mentored Clinical Scientist Development Award (K08), 1997-2002. Alfred Pope Award, McLean Hospital, 1997. Assistant Professor of Psychiatry (Neurology), Harvard Medical School, 1998-present. 8. Luis C. Maas, Ph.D. in Medical Engineering, Harvard-M.I.T Program in Biomedical Engineering. Scottish Rite Dissertation Award, 1995-1996. Athina Martinos Research Scholar, 1998. M.D., Harvard Medical School, 1999. Intern in Internal Medicine, Mount Auburn Hospital, 1999-2000. Resident in Radiology, University of California, San Francisco, CA, 2000-present. 9. Constance M. Moore, Ph.D. Post-doctoral fellow (physics) 1995-1997. Instructor in Psychiatry, Harvard Medical School, 1996-present. International Congress on Schizophrenia Research Young Investigator Award, 1997. NARSAD Young Investigator Award, 1998-2000. NIMH Mentored Career Development Award, 2001-2006. NARSAD Young Investigator Award, 2004-2006. Assistant Professor of Psychiatry, Harvard Medical School, 2003-present. 10. Srinivasan S. Pillay, M.D. Post-doctoral fellow (psychiatric neuroimaging) 1995-1996. APA/Lilly Research Award, 1997. Instructor in Psychiatry, Harvard Medical School, 1998-present. 11. Marc J. Kaufman, Ph.D. Post-doctoral fellow (alcohol and substance abuse) 1994-1995. National Institute on Drug Abuse Research Scientist Development Award, 1997-2002. Assistant Professor of Psychiatry, Harvard Medical School, 1997-present. Alfred Pope Award, McLean Hospital, 1998. 12. Lawrence L. Wald, Ph.D. Instructor in Psychiatry, Harvard Medical School, 1996-1998. Assistant Professor of Radiology, MGH-NMR Center, Charlestown, MA, 1998-present. 13. Christina Demopulos, M.D. Instructor in Psychiatry, Harvard Medical School, 1996-present. Assistant Psychiatrist, MGH Bipolar Research Program, Boston, MA, 1996-present. NARSAD Young Investigator Award, 1996-1998. 14. Ronald L.Cowan, M.D., Ph.D. Instructor in Psychiatry, Harvard Medical School, 1997-present. Assistant Physiologist and Assistant Psychiatrist, McLean Hospital Brain Imaging Center, 1997-present. APA/NIDA. Mentored Career Development Award, 1999-2003. Assistant Professor of Psychiatry, Vanderbilt University, School of Medicine, 2002-present. 15. Michael E. Henry, M.D. Instructor in Psychiatry, Harvard Medical School, 1996-present. Director, ECT Service, McLean Hospital, 1996-present. NIMH Mentored Career Development Award, 2002-2007. NIMH Mentored Career Development Award, 2003-2007. 11
  12. 12. Curriculum Vitae Perry Franklin Renshaw 16. Chris C. Streeter, M.D. Assistant Professor of Psychiatry, Boston University School of Medicine, 1997-present. VA Mentored Career Development Award, 1998-2001. NIAAA Mentored Career Development Award, 2001-2006. 17. Yong Ke, Ph.D. Instructor in Psychiatry, Harvard Medical School, 1998-present. NARSAD Young Investigator Award, 1999-2001. NARSAD Young Investigator Award, 2004-2006. 18. Aysegul Yildiz, M.D. Research Fellow in Psychiatry, Massachusetts General Hospital,1999- 2000. Assistant Professor of Psychiatry, University of Izmir, Turkey, 2000-present. ECNP Fellowship Award, 2002. Stanley Foundation Research Award, 2002. 19. Seong Yoon Kim, M.D., Ph.D. Visiting Research Fellow, Brain Imaging Center, McLean Hospital. Assistant Professor, Department of Psychiatry, University of Asan Medical College, 1997-present. 20. Carl M. Anderson, Ph.D. Instructor in Psychiatry, Harvard Medical School, 1998-present. NIDA Grant Award, 2002-2003. Assistant Professor of Psychiatry, Harvard Medical School, 2003-present. 21. Steven B. Lowen, Ph.D. Principal Associate, Harvard Medical School, 2000-present. NIDA funded Computational Neuroscience Competitive Supplement to “Magnetic Resonance, EEG, and Behavior After Cocaine”, 2001-2003. Assistant Professor of Psychiatry, Harvard Medical School, 2003-present. NIDA Mentored Quantitative Scientist Career Development Award, 2003-2008. 22. Lisa D. Nickerson, Ph.D. Post-doctoral fellow (physics), 2001-present. Drug Abuse Brain Imaging Fellow, 2002–2003, Assistant Physicist, McLean Hospital, Instructor in Psychiatry, Harvard Medical School, 2003-present. 23. David P. Olson, M.D., Ph.D. Instructor in Psychiatry, Harvard Medical School, 2002-present. Drug Abuse Brain Imaging Fellow, McLean Hospital Brain Imaging Center, 2003 - present. Assistant Psychiatrist, McLean Hospital, and Clinical Director, Brain Imaging Center, McLean Hospital, 2004-present. 24. J. Eric N. Jensen, Ph.D. Post-doctoral fellow (physics), 2002-present. NARSAD Young Investigator Award, 2004 – 2006. Assistant Physicist, McLean Hospital, Instructor in Psychiatry, Harvard Medical School, 2004-present. 25. Dan V. Iosifescu, M.D. Instructor in Psychiatry, Harvard Medical School, 2001-present. NARSAD Young Investigator Award, 2001-2003. NIMH Mentored Clinical Scientist Development Award, 2003-2008. 26. Brent Forester, M.D. Instructor in Psychiatry, Harvard Medical School, 2002-present. NARSAD Young Investigator Award, 2004-2006. 27. Chun Zuo, PhD. Assistant Professor in Psychiatry, Harvard Medical School, 2002-present. NARSAD Young Investigator Award, 2004-2006. 2. Regional, National, and International Contributions: Regional 1993 Grand Rounds, Department of Psychiatry, Salem Hospital, Salem, MA. Magnetic Resonance Imaging in Psychiatry. 12
  13. 13. Curriculum Vitae Perry Franklin Renshaw 1994 Grand Rounds, Department of Psychiatry, Salem Hospital, Salem, MA. Magnetic Resonance Imaging in Psychiatry. 1996 Invited Symposium Presentation. Clinical Investigator Training Program, Massachusetts Institute of Technology, Cambridge, MA. Magnetic Resonance Studies of Drug Effects. 1997 Invited Speaker, Departmental Research Seminar, Department of Psychology, Tufts University, Medford, MA. Fundamentals of fMRI. 1997 Grand Rounds, Department of Psychiatry. Newton-Wellesley Hospital, Newton, MA. MRS and fMRI in Neuropsychiatry. 2002 Invited Speaker, Partners Physicians Day, Boston, MA. Neuroimaging in the Future. 2002 Ground Rounds, Department of Psychiatry, Beth Israel Deaconess Hospital, Boston MA. MR Studies of Affective Illness. 2003 Grand Rounds, Department of Psychiatry, Tufts University, Medford, MA. Pyrimidines as Novel Therapies for Bipolar Disorder. National 1993 Grand Rounds, Department of Psychiatry, University of Texas, Southwestern, Dallas, TX. Magnetic Resonance Spectroscopy in Psychiatry. 1993 Grand Rounds, Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR. Magnetic Resonance Spectroscopy in Psychiatry. 1993 Grand Rounds, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA. Dynamic Susceptibility Contrast Imaging in Psychiatry. 1996 Invited Speaker, Departmental Research Seminar, Department of Psychiatry. University of Florida, Gainesville, FL. MR Studies in Psychiatry. 1997 Invited Symposium Speaker, Department of Psychiatry, Yale University School of Medicine, New Haven, CT. The Role of Brain Imaging Assessment for Dually-Diagnosed Persons. 1997 Grand Rounds, Department of Psychiatry, Wayne State University School of Medicine, Detroit, MI. MRS and Fri in Neuropsychiatry. 1998 Invited Symposium Presentation. Pritzker Foundation Research Network, Cornell University School of Medicine, N.Y., N.Y. Magnetic Resonance Studies of Depression. 1998 Invited Speaker, Research Seminar, Biophysics Research Center, Medical College of Wisconsin, Milwaukee, WI. Magnetic Resonance Studies of Drug Abuse. 13
  14. 14. Curriculum Vitae Perry Franklin Renshaw 1999 Grand Rounds, Department of Psychiatry, University of Cincinnati School of Medicine, Cincinnati, OH. MRS and fMRI in Neuropsychiatry. 1999 Pfizer Visiting Professor, Department of Psychiatry, Mt. Sinai School of Medicine, N.Y, N.Y. MRS and fMRI in Neuropsychiatry. 1999 Symposium Co-Chair, Neuroscience and Neuroimaging, International Conference on Bipolar Disorder, Pittsburgh, PA. Multinuclear MRS Studies of Bipolar Disorder. 1999 Invited Speaker, Research Seminar, Department of Psychiatry, University of California at Davis, CA. MRS and fMRI in Neuropsychiatry. 1999 Invited Speaker, Workshop on Magnetic Resonance and Optical Imaging Techniques for Biomedical Applications, Metabolic Magnetic Resonance Research and Computing Center, Department of Radiology, University of Pennsylvania, Philadelphia, PA. Psychiatric Applications of fMRI and MRS. 1999 Invited Speaker, Neurodevelopmental Sequelae of Drug Abuse in Child and Adolescent Populations. National Institute on Drug Abuse, Rockville, MD. Practical Aspects of Imaging Drug-Exposed Children and Adolescents. 1999 Symposium Speaker, Research Society on Alcoholism, Santa Barbara, CA. Overview of MRS Studies on Alcoholism. 1999 Symposium Speaker, Annual Meeting of the American Psychiatric Association, Washington, D.C. Magnetic Resonance Studies of Drug Abuse and Dependence. 2000 Invited Speaker, American College of Addiction Psychiatry, Phoenix, AR. Magnetic Resonance Studies of Drug Abuse and Dependence. 2000 Invited Speaker, Seminar in Neuroscience and Biophysics. University of South Florida, Tampa, FL. MRS and fMRI in Neuropsychiatry. 2000 Invited Speaker, Departmental Research Seminar, Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA. The Role of Magnetic Resonance in Psychiatry. 2001 Invited Speaker, Research Seminar, Department of Psychiatry, University of Indiana University, School of Medicine, Indianapolis, IN. MRS and fMRI in Neuropsychiatry. 2001 Invited Speaker, Research Seminar, Department of Radiology, University of Pennsylvania, School of Medicine, Philadelphia, PA. Psychiatric Magnetic Resonance Research. 2001 Pfizer Visiting Professor, Department of Psychiatry, University of Mississippi, School of Medicine, Jackson, Mississippi. High Field Magnetic Resonance Research in Psychiatry. 2001 Invited Speaker, Medical Imaging in Clinical Trials, Drug Information Association, Washington, DC. Imaging in Psychiatric Drug Development. 14
  15. 15. Curriculum Vitae Perry Franklin Renshaw 2001 Grand Rounds, Department of Psychiatry, Wayne State University, Detroit, MI. MRS and fMRI in Neuropsychiatry. 2001 Invited Speaker, Neuroimaging Training Program, Yale University, New Haven, CT. MR Studies in Psychiatry. 2002 Invited Speaker, Medical Department, Brookhaven National Laboratories, Brookhaven, NY. MR Research in Drug Abuse: Recent Findings. 2002 Invited Speaker, Fundamentals of MRS Teaching Course, International Society of Magnetic Resonance in Medicine, Honolulu, HI. Psychiatric MRS. 2002 Invited Speaker, Advanced Brain Imaging Techniques Teaching Course, International Society of Magnetic Resonance in Medicine, Honolulu, HI. Magnetic Resonance Studies of Psychiatric Disorders. 2002 Invited Speaker, Drug Information Association, Boston, MA. Flourine-19 MRS in Drug Development. 2002 Grand Rounds, Department of Psychiatry, University of California, Los Angeles, CA. MRS & fMRI in Neuropsychiatry. 2003 Grant Rounds, Department of Psychiatry, University of Texas Health Science Center, Houston, Texas. MRI Studies of Affective Illness. 2004 Invited Speaker, Society for Non-invasive Imaging in Drug Development, Bethlehem, PA. MR Studies in Psychiatry. 2005 Grand Rounds, McLean Hospital, Belmont, MA. Magnetic Resonance Spectroscopy Studies of Affective Illness. International 1996 Invited Speaker, Advances in Magnetic Resonance Contrast Agents, Barcelona, Spain. Dynamic Susceptibility Contrast MRI for the Assessment of Alzheimer’s Disease. 1997 Symposium Speaker, Collegium Internationale Neurosychopharmacologicum, Brussels, Belgium. Brain Chemical Abnormalities in Mood Disorders. 1997 Invited Speaker, Teaching Day, American College of Neuropsychopharmacology. San Juan Puerto Rico. MRS in Psychopharmacology Research. 1997 Invited Speaker, Teaching Lecture, College on Problems of Drug Dependence, San Juan, Puerto Rico. Nuts and Bolts of Brain Imaging. 1997 Stanley Foundation Visiting Professor, Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada. Nuts and Bolts of Brain Imaging. 1997 Symposium Co-Chair and Keynote Speaker, International Society of Magnetic Resonance in Medicine, Sydney, Australia. MR Research Findings in Psychiatry. 15
  16. 16. Curriculum Vitae Perry Franklin Renshaw 1998 Symposium Speaker, Annual Meeting of the American Psychiatric Association, Toronto, Canada. Magnetic Resonance Studies of Bipolar Disorder. 1999 Invited Speaker, Pharmacopsychiatry Section, World Psychiatric Association, Hamburg, Germany. MRS Studies of Brain Drug Levels in Man. 2001 Invited Speaker, Fundamentals of MRS, Teaching Course, International Society of Magnetic Resonance in Medicine, Glasgow, U.K. Psychiatric MRS. 2001 Invited Speaker, Advanced Brain Imaging Techniques Teaching Course, International Society of Magnetic Resonance in Medicine, Glasgow, U.K. Magnetic Resonance Studies of Psychiatric Disorders. 2001 Seminar Speaker, Departments of Psychiatry and Radiology, University of British Columbia, Vancouver, Canada. MRS and fMRI Studies in Psychiatry. 2002 Invited Speaker, ASNR 40th Annual Meeting, Vancouver, British Columbia. MRS and fMRI in Psychiatry: Clinical Relevance or Irrational Exuberance? 2002 Invited Speaker, Bipolar Global Medical Conference, Monte Carlo, Monaco. MR Studies of Bipolar Disorder: Toward a Bioenergetic Perspective. 2002 Invited Speaker, AMEA/CEE Regional Neuroscience Conference, Neuroscience Conference, St. Julians, Malta. MRS Studies of Schizophrenia. 2002 Invited Symposium Speaker, World Psychiatric Association, Yokohama, Japan. MRS Studies of Schizophrenia. 2002 Invited Speaker, Hangany University, Department of Biomedical Engineering, Seoul, South Korea. Functional Magnetic Resonance Imaging. 2003 Invited Speaker, NATO Advanced Research Workshop on Psychiatric Neuroimaging, Chiavari, Italy. MRS Studies in Psychiatry. 2003 Invited Speaker, Collaborative Research Meeting, National Institute on Drug Abuse, Cape Town, South Africa. MR Studies of Drug Dependence. 2003 Invited Speaker, Basic MRS Teaching Course. International Society of Magnetic Resonance in Medicine, Toronto, Canada. Psychiatric MRS. 2003 Invited Speaker, National Institute of Neurology, Mexico City, Mexico, Clinical Functional Magnetic Resonance Imaging. 2004 Co-Chair and Invited Speaker, International Congress of Biological Psychiatry, Sydney, Australia, The Future of MRS in Psychiatry. PART III: BIBLIOGRAPHY: Original Articles: 1. Renshaw PF, Janoff AS, Miller KW. On the nature of dilute aqueous cholesterol suspensions. Journal of Lipid Research. 1983; 24(1): 47-51. 16
  17. 17. Curriculum Vitae Perry Franklin Renshaw 2. Renshaw PF, Haselgrove JC, Leigh JS, Chance B. In vivo nuclear magnetic resonance imaging of lithium. Magnetic Resonance in Medicine. 1985; 2(5): 512-16. 3. Renshaw PF, Haselgrove JC, Bolinger L, Chance B, Leigh JS, Jr. Relaxation and imaging of lithium in vivo. Magnetic Resonance Imaging. 1986; 4(3): 193-98. 4. Renshaw PF, Owen CS, Evans AE, Leigh JS, Jr. Immunospecific NMR contrast agents. Magnetic Resonance Imaging. 1986; 4(4): 351-57. 5. Renshaw PF, Owen CS, McLaughlin AC, Frey TG, Leigh JS, Jr. Ferromagnetic contrast agents: a new approach. Magnetic Resonance in Medicine. 1986; 3(2): 217-25. 6. Renshaw PF, Summers JJ, Renshaw CE, Hines KG, Leigh JS, Jr. Changes in the 31P-NMR spectra of cats receiving lithium chloride systemically. Biological Psychiatry.1986; 21(7): 694-98. 7. Renshaw PF, Joseph NE, Leigh JS, Jr. Chronic dietary lithium induces increased levels of myo-inositol-1-phosphatase activity in rat cerebral cortex homogenates. Brain Research. 1986; 380(2): 401-44. 8. Renshaw PF, Blum H, Leigh JSJ. Applications of dextran-magnetite as a sodium relaxation enhancer in biological systems. Journal of Magnetic Resonance. 1986; 69: 523-27. 9. Renshaw PF. A diffusional contribution to lithium isotope effects. Biological Psychiatry. 1987; 22(1): 73-8. 10. Schnall MD, Bolinger L, Renshaw PF, Haselgrove JC, Subramanian VH, Eleff SM, Barlow C, Leigh JS, Jr., Chance B. Multinuclear MR imaging: a technique for combined anatomic and physiologic studies. Radiology. 1987; 162(3): 863-66. 11. Pekar J, Renshaw PF, Leigh JSJ. Selective detection of intracellular sodium by coherence- transfer NMR. Journal of Magnetic Resonance. 1987; 72: 159-62. 12. Renshaw PF, Schnall MD, Leigh JS, Jr. In vivo 31P NMR spectroscopy of agonist-stimulated phosphatidylinositol metabolism in cat brain. Magnetic Resonance in Medicine.1987; 4(3):221-26. 13. Joseph NE, Renshaw PF, Leigh JS, Jr. Systemic lithium administration alters rat cerebral cortex phospholipids. Biological Psychiatry. 1987; 22(5): 540-44. 14. Renshaw PF, Wicklund S. In vivo measurement of lithium in humans by nuclear magnetic resonance spectroscopy. Biological Psychiatry. 1988; 23(5): 465-75. 15. Argov Z, Renshaw PF, Boden B, Winokur A, Bank WJ. Effects of thyroid hormones on skeletal muscle bioenergetics. In vivo phosphorus-31 magnetic resonance spectroscopy study of humans and rats. Journal of Clinical Investigation. 1988; 81(6): 1695-701. 16. Summers RM, Joseph PM, Renshaw PF, Kundel HL. Dextran-magnetite: a contrast agent for sodium-23 MRI. Magnetic Resonance in Medicine. 1988; 8(4): 427-39. 17. Blum H, Schnall MD, Renshaw PF, Buzby GP. Metabolic and ionic changes in muscle during hemorrhagic shock. Circulatory Shock. 1988; 26(4): 341-51. 18. Pies R, Renshaw PF, Goff DC, Metz A, Bachovin W, Hotz R, Shader RI. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma from schizophrenics and normal 17
  18. 18. Curriculum Vitae Perry Franklin Renshaw controls: A preliminary report. Research Communications in Psychology, Psychiatry, and Behavior. 1992; 17: 25-32. 19. Renshaw PF, Stern TA, Welch C, Schouten R, Kolodny EH. Electroconvulsive therapy treatment of depression in a patient with adult GM2 gangliosidosis. Annals of Neurology. 1992; 31(3): 342-44. 20. Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR, Clancy K, Gonzalez RG. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. American Journal of Psychiatry. 1992; 149(11): 1592-94. 21. Stoll AL, Renshaw PF, Sachs GS, Guimaraes AR, Miller C, Cohen BM, Lafer B, Gonzalez RG. The human brain resonance of choline-containing compounds is similar in patients receiving lithium treatment and controls: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry. 1992; 32(10): 944-49. 22. Halman MH, Worth JL, Sanders KM, Renshaw PF, Murray GB. Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection. Journal of Neuropsychiatry & Clinical Neurosciences. 1993; 5(4): 430-34. 23. Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA. A placebo- controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biological Psychiatry. 1993; 33(10): 700-06. 24. Gonzalez RG, Guimaraes AR, Sachs GS, Rosenbaum JF, Garwood M, Renshaw PF. Measurement of human brain lithium in vivo by MR spectroscopy. American Journal of Neuroradiology. 1993; 14(5): 1027-37. 25. Semrud-Clikeman M, Filipek PA, Biederman J, Steingard R, Kennedy D, Renshaw PF, Bekken K. Attention deficit hyperactivity disorder: MRI morphometric analysis of the corpus callosum. Journal of the American Academy of Child & Adolescent Psychiatry. 1994; 33: 875-81. 26. Renshaw PF, Yurgelun-Todd DA, Cohen BM. Greater hemodynamic response to photic stimulation in schizophrenic patients: an echo planar MRI study. American Journal of Psychiatry. 1994; 151(10): 1493-95. 27. Stoll AL, Renshaw PF, De Micheli E, Wurtman R, Pillay SS, Cohen BM. Choline ingestion increases the resonance of choline-containing compounds in human brain: an in vivo proton magnetic resonance study. Biological Psychiatry. 1995; 37(3): 170-74. 28. Renshaw PF, Yurgelun-Todd DA, Tohen M, Gruber S, Cohen BM. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. American Journal of Psychiatry. 1995; 152(3): 444-46. 29. Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, Yurgelun-Todd DAB, S.M. Markedly decreased brain choline uptake in older adults: An in vivo proton magnetic resonance spectroscopy study. Journal of the American Medical Association. 1995; 274: 902-07. 30. Sachs GS, Renshaw PF, Lafer B, Stoll AL, Guimaraes AR, Rosenbaum JF, Gonzalez RG. Variability of brain lithium levels during maintenance treatment: a magnetic resonance spectroscopy study. Biological Psychiatry. 1995; 38(7): 422-28. 31. Levin JM, Kaufman MJ, Ross MH, Mendelson JH, Maas LC, Cohen BM, Renshaw PF. Sequential dynamic susceptibility contrast MR experiments in human brain: residual contrast 18
  19. 19. Curriculum Vitae Perry Franklin Renshaw agent effect, steady state, and hemodynamic perturbation. Magnetic Resonance in Medicine. 1995; 34(5): 655-63. 32. Cohen BM, Yurgelun-Todd D, English CD, Renshaw PF. Abnormalities of regional distribution of cerebral vasculature in schizophrenia detected by dynamic susceptibility contrast MRI. American Journal of Psychiatry. 1995; 152(12): 1801-03. 33. Lyoo IK, Seol HY, Byun HS, Renshaw PF. Unsuspected multiple sclerosis in patients with psychiatric disorders: a magnetic resonance imaging study. Journal of Neuropsychiatry & Clinical Neurosciences. 1996; 8(1): 54-59. 34. Yurgelun-Todd DA, Waternaux CM, Cohen BM, Gruber SA, English CD, Renshaw PF. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. American Journal of Psychiatry. 1996; 153(2): 200-05. 35. Yurgelun-Todd DA, Renshaw PF, Gruber SA, Ed M, Waternaux C, Cohen BM. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophrenia Research. 1996; 19(1): 55-59. 36. Steingard RJ, Renshaw PF, Yurgelun-Todd D, Appelmans KE, Lyoo IK, Shorrock KL, Bucci JP, Cesena M, Abebe D, Zurakowski D, Poussaint TY, Barnes P. Structural abnormalities in brain magnetic resonance images of depressed children. Journal of the American Academy of Child & Adolescent Psychiatry. 1996; 35(3): 307-11. 37. Christensen JD, Kaufman MJ, Levin JM, Mendelson JH, Holman BL, Cohen BM, Renshaw PF. Abnormal cerebral metabolism in polydrug abusers during early withdrawal: a 31P MR spectroscopy study. Magnetic Resonance in Medicine. 1996; 35(5): 658-63. 38. Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA, Renshaw PF. Dynamic susceptibility contrast MRI of regional cerebral blood volume in Alzheimer's disease. American Journal of Psychiatry. 1996; 153(5): 721-24. 39. Babb SM, Appelmans KE, Renshaw PF, Wurtman RJ, Cohen BM. Differential effect of CDP- choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology. 1996; 127(2): 88-94. 40. Keltner JR, Wald LL, Christensen JD, Maas LC, Moore CM, Cohen BM, Renshaw PF. A technique for detecting GABA in the human brain with PRESS localization and optimized refocusing spectral editing radio frequency pulses. Magnetic Resonance in Medicine. 1996; 36(3): 458-61. 41. Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium- treated patients. Biological Psychiatry. 1996; 40(5): 382-88. 42. Lyoo IK, Noam GG, Lee CK, Lee HK, Kennedy BP, Renshaw PF. The corpus callosum and lateral ventricles in children with attention-deficit hyperactivity disorder: a brain magnetic resonance imaging study. Biological Psychiatry. 1996; 40(10): 1060-63. 43. Ross MH, Yurgelun-Todd DA, Renshaw PF, Maas LC, Mendelson JH, Mello NK, Cohen BM, Levin JM. Age-related reduction in functional MRI response to photic stimulation. Neurology. 1997; 48(1): 173-76. 19
  20. 20. Curriculum Vitae Perry Franklin Renshaw 44. Maas LC, Frederick BD, Renshaw PF. Decoupled automated rotational and translational registration for functional MRI time series data: the DART registration algorithm. Magnetic Resonance in Medicine. 1997; 37(1): 131-39. 45. Maas LC, Harris GJ, Satlin A, English CD, Lewis RF, Renshaw PF. Regional cerebral blood volume measured by dynamic susceptibility contrast MR imaging in Alzheimer's disease: a principal components analysis. Journal of Magnetic Resonance Imaging. 1997; 7(1): 215-19. 46. Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. American Journal of Psychiatry. 1997; 154(1): 116-18. 47. English CD, Kaufman MJ, Worth JL, Babb SM, Drebing CE, Navia BA, Renshaw PF. Elevated frontal lobe cytosolic choline levels in minimal or mild AIDS dementia complex patients: a proton magnetic resonance spectroscopy study. Biological Psychiatry. 1997; 41(4): 500-02. 48. Filipek PA, Semrud-Clikeman M, Steingard RJ, Renshaw PF, Kennedy DN, Biederman J. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology. 1997; 48(3): 589-601. 49. Keltner JR, Wald LL, Frederick BD, Renshaw PF. In vivo detection of GABA in human brain using a localized double-quantum filter technique. Magnetic Resonance in Medicine. 1997; 37(3): 366-71. 50. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD, Moore CM, Yurgelun- Todd DA, Bonello CM, Pillay SS, Rothschild AJ, Nierenberg AA, Rosenbaum JF, Cohen BM. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry. 1997; 41(8): 837-43. 51. Lyoo IK, Satlin A, Lee CK, Renshaw PF. Regional atrophy of the corpus callosum in subjects with Alzheimer's disease and multi-infarct dementia. Psychiatry Research. 1997; 74(2): 63-72. 52. Frederick BB, Satlin A, Yurgelun-Todd DA, Renshaw PF. In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biological Psychiatry. 1997; 42(2): 147-50. 53. Pillay SS, Yurgelun-Todd DA, Bonello CM, Lafer B, Fava M, Renshaw PF. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Biological Psychiatry. 1997; 42(2): 79-84. 54. Satlin A, Bodick N, Offen WW, Renshaw PF. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. American Journal of Psychiatry. 1997; 154(10): 1459-61. 55. Christensen JD, Babb SM, Cohen BM, Renshaw PF. Quantitation of dexfenfluramine/d- norfenfluramine concentration in primate brain using 19F NMR spectroscopy. Magnetic Resonance in Medicine. 1998; 39(1):149-54. 56. Maas LC, Lukas SE, Kaufman MJ, Weiss RD, Daniels SL, Rogers VW, Kukes TJ, Renshaw PF. Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. American Journal of Psychiatry. 1998; 155(1):124-26. 20
  21. 21. Curriculum Vitae Perry Franklin Renshaw 57. Levin JM, Wald LL, Kaufman MJ, Ross MH, Maas LC, Renshaw PF. T1 effects in sequential dynamic susceptibility contrast experiments. Journal of Magnetic Resonance.1998; 130(2):292-95. 58. Kaufman MJ, Levin JM, Ross MH, Lange N, Rose SL, Kukes TJ, Mendelson JH, Lukas SE, Cohen BM, Renshaw PF. Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. Journal of the American Medical Association. 1998; 279(5):376-80. 59. Sholar MB, Mendelson JH, Mello NK, Siegel AJ, Kaufman MJ, Levin JM, Renshaw PF, Cohen BM. Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men. Journal of Clinical Endocrinology & Metabolism. 1998; 83(3):966-68. 60. Levin JM, Ross MH, Mendelson JH, Mello NK, Cohen BM, Renshaw PF. Sex differences in blood-oxygenation-level-dependent functional MRI with primary visual stimulation. American Journal of Psychiatry. 1998; 155(3):434-36. 61. Streeter CC, Ciraulo DA, Harris GJ, Kaufman MJ, Lewis RF, Knapp CM, Ciraulo AM, Maas LC, Ungeheuer M, Szulewski S, Renshaw PF. Functional magnetic resonance imaging of alprazolam-induced changes in humans with familial alcoholism. Psychiatry Research. 1998; 82(2):69-82. 62. Levin JM, Ross MH, Mendelson JH, Kaufman MJ, Lange N, Maas LC, Mello NK, Cohen BM, Renshaw PF. Reduction in BOLD fMRI response to primary visual stimulation following alcohol ingestion. Psychiatry Research. 1998; 82(3):135-46. 63. Kaufman MJ, Levin JM, Maas LC, Rose SL, Lukas SE, Mendelson JH, Cohen BM, Renshaw PF. Cocaine decreases relative cerebral blood volume in humans: a dynamic susceptibility contrast magnetic resonance imaging study. Psychopharmacology. 1998; 138(1):76-81. 64. Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA, Renshaw PF. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. American Journal of Neuroradiology. 1998; 19(9):1727-32. 65. Kaufman MJ, Siegel AJ, Mendelson JH, Rose SL, Kukes TJ, Sholar MB, Lukas SE, Renshaw PF. Cocaine administration induces human splenic constriction and altered hematologic parameters. Journal of Applied Physiology. 1998; 85(5):1877-83. 66. Pillay SS, Renshaw PF, Bonello CM, Lafer BC, Fava M, Yurgelun-Todd D. A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Psychiatry Research. 1998; 84(2-3):61-74. 67. Wald LL, Frederick B, Renshaw PF. NAA-weighted imaging of the human brain using a conventional readout gradient. Magnetic Resonance in Medicine. 1999; 41(1):187-92. 68. Frederick Bd, Wald LL, Maas LC, 3rd, Renshaw PF. A phased array echoplanar imaging system for fMRI. Magnetic Resonance Imaging. 1999; 17(1): 121-29. 21
  22. 22. Curriculum Vitae Perry Franklin Renshaw 69. Renshaw PF, Daniels S, Lundahl LH, Rogers V, Lukas SE. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology. 1999; 142(2): 132-38. 70. Baird AA, Gruber SA, Fein DA, Maas LC, Steingard RJ, Renshaw PF, Cohen BM, Yurgelun- Todd DA. Functional magnetic resonance imaging of facial affect recognition in children and adolescents. Journal of the American Academy of Child & Adolescent Psychiatry. 1999; 38(2): 195-99. 71. Moore CM, Breeze JL, Kukes TJ, Rose SL, Dager SR, Cohen BM, Renshaw PF. Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry. 1999; 45(9):1197-202. 72. Loeber RT, Sherwood AR, Renshaw PF, Cohen BM, Yurgelun-Todd DA. Differences in cerebellar blood volume in schizophrenia and bipolar disorder. Schizophrenia Research. 1999; 37(1):81-9. 73. Kaufman MJ, Pollack MH, Villafuerte RA, Kukes TJ, Rose SL, Mendelson JH, Cohen BM, Renshaw PF. Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance. Psychiatry Research. 1999; 90(3): 143-52. 74. Christensen JD, Yurgelun-Todd DA, Babb SM, Gruber SA, Cohen BM, Renshaw PF. Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy. Brain Research. 1999; 834(1-2): 1-5. 75. Mendelson JH, Mello NK, Sholar MB, Siegel AJ, Kaufman MJ, Levin JM, Renshaw PF, Cohen BM. Cocaine pharmacokinetics in men and in women during the follicular and luteal phases of the menstrual cycle. Neuropsychopharmacology. 1999; 21(2): 294-303. 76. Siegel AJ, Sholar MB, Mendelson JH, Lukas SE, Kaufman MJ, Renshaw PF, McDonald JC, Lewandrowski KB, Apple FS, Stec JJ, Lipinska I, Tofler GH, Ridker PM. Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood doping and prothrombotic effects. Archives of Internal Medicine. 1999; 159(16): 1925-29. 77. Fava M, Rosenbaum JF, Kolsky AR, Alpert JE, Nierenberg AA, Spillmann M, Moore C, Renshaw PF, Bottiglieri T, Moroz G, Magni G. Open study of the catechol-O- methyltransferase inhibitor tolcapone in major depressive disorder. Journal of Clinical Psychopharmacology. 1999; 19: 329-33. 78. Sonawalla SB, Renshaw PF, Moore CM, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. American Journal of Psychiatry. 1999; 156(10): 1638-40. 79. Maas LC, Renshaw PF. Post-registration spatial filtering to reduce noise in functional MRI data sets. Magnetic Resonance Imaging. 1999; 17(9): 1371-82. 80. Kinney DK, Steingard RJ, Renshaw PF, Yurgelun-Todd DA. Perinatal complications and abnormal proton metabolite concentrations in frontal cortex of adolescents seen on magnetic resonance spectroscopy. Neuropsychiatry, Neuropsychology, & Behavioral Neurology. 2000; 13(1): 8-12. 81. Kaufman MJ, Levin JM, Kukes TJ, Villafuerte RA, Hennen J, Lukas SE, Mendelson JH, Renshaw PF. Illicit cocaine use patterns in intravenous-naive cocaine users following investigational intravenous cocaine administration. Drug & Alcohol Dependence. 2000; 58 (1-2):35-42. 22
  23. 23. Curriculum Vitae Perry Franklin Renshaw 82. Teicher MH, Anderson CM, Polcari A, Glod CA, Maas LC, Renshaw PF. Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nature Medicine. 2000; 6(4): 470-73. 83. Semrud-Clikeman M, Steingard RJ, Filipek P, Biederman J, Bekken K, Renshaw PF. Using MRI to examine brain-behavior relationships in males with attention deficit disorder with hyperactivity. Journal of the American Academy of Child & Adolescent Psychiatry. 2000; 39(4): 477-84. 84. Vakili K, Pillay SS, Lafer B, Fava M, Renshaw PF, Bonello-Cintron CM, Yurgelun-Todd DA. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biological Psychiatry. 2000; 47(12): 1087-90. 85. Moore CM, Breeze JL, Gruber SA, Babb SM, Frederick BB, Villafuerte RA, Stoll AL, Hennen J, Yurgelun-Todd DA, Cohen BM, Renshaw PF. Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulate cortex. Bipolar Disorders. 2000; 2(3 Pt 2) 207-16. 86. Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, Vuckevic AJ, Berreira PJ, Cohen BM, Renshaw PF. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. American Journal of Psychiatry. 2000; 157(9): 1506-08. 87. Christensen JD, Kaufman MJ, Frederick B, Rose SL, Moore CM, Lukas SE, Mendelson JH, Cohen BM, Renshaw PF. Proton magnetic resonance spectroscopy of human basal ganglia: response to cocaine administration. Biological Psychiatry. 2000; 48(7): 685-92. 88. Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore CM, Vakili K, Young AD, Katic A, Beardslee WR, Renshaw PF. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biological Psychiatry. 2000; 48(11): 1053-61. 89. Cowan RL, Frederick BB, Rainey M, Levin JM, Maas LC, Bang J, Hennen J, Lukas SE, Renshaw PF. Sex differences in response to red and blue light in human primary visual cortex: a bold fMRI study. Psychiatry Research. 2000; 100(3): 129-38. 90. Ke Y, Cohen BM, Bang JY, Yang M, Renshaw PF. Assessment of GABA concentration in human brain using two-dimensional proton magnetic resonance spectroscopy. Psychiatry Research. 2000; 100(3): 169-78. 91. Kaufman MJ, Levin JM, Maas LC, Kukes TJ, Villafuerte RA, Dostal K, Lukas SE, Mendelson JH, Cohen BM, Renshaw PF. Cocaine-induced cerebral vasoconstriction differs as a function of sex and menstrual cycle phase. Biological Psychiatry. 2001; 49(9): 774-81. 92. Yildiz A, Sachs GS, Dorer DJ, Renshaw PF. 31P Nuclear magnetic resonance spectroscopy findings in bipolar illness: a meta-analysis. Psychiatry Research. 2001; 106(3): 181-91. 93. Henry ME, Kaufman MJ, Lange N, Schmidt ME, Purcell S, Cote J, Perron-Henry DM, Stoddard E, Cohen BM, Renshaw PF. Test-retest reliability of DSC MRI CBV mapping in healthy volunteers. NeuroReport. 2001; 12(8): 1567-69. 23
  24. 24. Curriculum Vitae Perry Franklin Renshaw 94. Yildiz A, Demopulos CM, Moore CM, Renshaw PF, Sachs GS. Effect of lithium on phosphoinositide metabolism in human brain: a proton decoupled (31)P magnetic resonance spectroscopy study. Biological Psychiatry. 2001; 50(1): 3-7. 95. Lukas SE, Kouri EM, Rhee C, Madrid A, Renshaw PF. Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. Psychopharmacology (Berl.). 2001; 157:163-67. 96. Levin JM, Frederick Bde B, Ross MH, Fox JF, von Rosenberg HL, Kaufman MJ, Lange N, Mendelson JH, Cohen BM, Renshaw PF. Influence of baseline hematocrit and hemodilution on BOLD fMRI activation. Magnetic Resonance Imaging. 2001; 19(8): 1055-62. 97. Renshaw PF, Parow AM, Hirashima F, Ke Y, Moore CM, Frederick Bde B, Fava M, Hennen J, Cohen BM. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. American Journal of Psychiatry. 2001; 158(12): 2048-55. 98. Anderson CM, Teicher MH, Polcari A, Renshaw PF. Abnormal T2 relaxation time in the cerebellar vermis of adults sexually abused in childhood: potential role of the vermis in stress- enhanced risk for drug abuse. Psychoneuroendocrinology. 2002; 27(1-2): 231-44. 99. Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. American Journal of Geriatric Psychiatry 2002; 10(1):81-8. 100. Ke Y, Cohen BM, Lowen S, Hirashima F, Nasser L, Renshaw P. Biexponential transverse relaxation (T2) of the proton MRS creatine resonance in human brain. Magnetic Resonance in Medicine 2002; 47:232-38. 101. Loeber RT, Gruber SA, Cohen BM, Renshaw PF, Sherwood AR, Yurgelun-Todd DA. Cerebellar blood volume in bipolar patients correlates with medication. Biological Psychiatry 2002; 51:370-76. 102. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biological Psychiatry 2002; 51(6):493-97. 103. Streeter CC, Gulliver SB, Baker E, Blank SR, Meyer AA, Ciraulo DA, Renshaw PF. Videotaped cue for urge to drink alcohol. Alcoholism: Clinical and Experimental Research 2002; 26(5): 627-34. 104. Babb SM, Wald LL, Cohen BM, Villafuerte RA, Gruber SA, Yurgelun-Todd DA, Renshaw PF. Chronic citicoline increases phosphodiesters in the brain of healthy older adults: An in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology 2002; 161(3): 248-54. 105. Carlezon WA, Pliakas AM, Parow AM, Detke MJ, Cohen BM, Renshaw PF. Antidepressant-like effects of cytidine in the forced swim test in rats. Biological Psychiatry 2002; 51(11): 882-89. 106. Moore CM, Demopulos CM, Henry ME, Steingard RJ, Zamvil L, Katic A, Breeze JL, Moore JC, Cohen BM, Renshaw PF. Brain-to-serum lithium ratio and age: An in vivo lithium magnetic resonance spectroscopy study. American Journal of Psychiatry 2002; 159(7): 1240-42. 107. Anderson CM, Polcari A, Lowen S, Renshaw PF, Teicher MH. Effects of methylphenidate on functional magnetic resonance relaxometry of the cerebellar vermis in children with ADHD. American Journal of Psychiatry 2002; 159(8): 1322-28. 24
  25. 25. Curriculum Vitae Perry Franklin Renshaw 108. Steingard RJ, Renshaw PF, Hennen J, Lenox M, Vakili K, Young AD, Connor DF, Yurgelun- Todd DA. Smaller frontal lobe white matter in depressed adolescents. Biological Psychiatry 2002; 52(5): 413-17. 109. Lyoo IK, Kwon JS, Lee SJ, Han MH, Chang C-G, Seo CS, Lee SI, Renshaw PF. Decrease in genu of the corpus callosum in medication-naïve early-onset dysthymia and depressive personality disorder. Biological Psychiatry 2002; 52(12) 1134-43. 110. Lyoo IK, Lee HK, Jung JH, Noam GG, Renshaw PF. White matter hyperintensities on magnetic resonance imaging of the brain in children with psychiatric disorders. Comprehensive Psychiatry 2002; 43(5): 361-68. 111. Moore CM, Bonello CM, Sherwood AR, Cohen BM, Renshaw PF, Yurgulen-Todd DA. Mesial temporal lobe Cho to Cr (PCr) ratio asymmetry in chronic schizophrenics. Schizophrenia Research 2002; 57(1): 35-42. 112. Lyoo IK, PF Renshaw. Magnetic Resonance Spectroscopy: current and future applications in psychiatric research. Biological Psychiatry 2002; 51:195-207 113. Henry ME, Kaufman MJ, Hennen J, Michelson D, Schmidt ME, Stoddard E, Vukovic AJ, Barreira PJ, Cohen BM, Renshaw PF. Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment. Biological Psychiatry 2003; 53: 100-05. 114. Ke Y, Streeter C, Lowen S, Nassar LE, Parow AM, Hennen J, Yurgelun-Todd DA, Sarid-Segal O, Awad LA, Rendall M, Gruber SA, Nason A, Mudrick MJ, Blank SR, Ciraulo DA, Renshaw PF. Increased frontal lob phosphocreatine levels observed in heavy cocaine users after treatment for cocaine dependence- An 1H MRS T2 relaxometry study. Spectroscopy 2003; 17: 231-39. 115. Lyoo IK, Kong SW, Hirashima F, Parow AM, Sung SM, Cohen BM, Renshaw PF. Multinuclear magnetic resonance spectroscopy of high energy phosphate metabolites in human brain following creatine oral supplementation of creatine monohydrate. Psychiatry Research: Neuroimaging 2003; 123(2): 87-100. 116. Silveri MM, Parow AM, Villafuerte RA, Damico KE, Goren J, Stoll AL, Cohen BM, Renshaw PF. Oral treatment with S-adenosyl-L-methionine: Effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biological Psychiatry 2003; 54(8): 833-39. 117. Lyoo IK, Demopulos CM, Hirashima F, Renshaw PF. Oral choline decreases brain purine levels in lithium-treated subjects with rapid-cycling bipolar disorder. A double-blind trial using proton and lithium magnetic resonance spectroscopy. Bipolar Disorders 2003; 5 (4): 300- 06. 118. Dorsey CM, Lukas SE, Moore CM, Tartarini WL, Parow AM, Villafuerte RA, Renshaw PF. Phosphorous 31 magnetic resonance spectroscopy after total sleep deprivation in healthy adult men. Sleep 2003; 26(5): 573-77. 119. Cowan RL, Lyoo IK, Sung SM, Ahn KH, Kim JM, Haga E, Vimal RL, Lukas SE, Renshaw PF. Reduced cortical gray mater density in human MDMA (Ecstasy) users: A voxel-based morphometry study. Drug & Alcohol Dependence 2003; 72(3): 225-35. 120. Fabbri F, Henry ME, Renshaw PF, Nadgir S, Ehrenberg BL, Franceschini MA, Fantini S. 25
  26. 26. Curriculum Vitae Perry Franklin Renshaw Bilateral near-infrared monitoring of the cerebroconcentration and oxygen saturation of hemoglobin during review of unilateral electroconvulsive therapy. Brain Research 2003; 992(2): 193-04. 121. Kaufman MJ, Henry ME, Frederick B, Hennen J, Villafuerte RA, Stoddard EP, Schmidt ME, Cohen MB, Renshaw PF. Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: proton magnetic resonance spectroscopic imaging study. Biological Psychiatry 2003; 54(5): 534-39. 122. Ehrlich S, Noam GG, Lyoo IK, Kwon BJ, Clark MA, Renshaw PF. Subanalysis of the location of white matter hyperintensities and their association with suicidality in children and youth. Ann NY Academy of Science 2003; 1008: 265-68. 123. Rohan ML, Parow AM, Stoll AL, Demopulos CM, Friedman SD, Dager SR, Hennen J, Cohen BM, Renshaw PF. Low field magnetic stimulation in bipolar depression using a MRI based stimulator. American Journal of Psychiatry 2004; 161: 93-8. 124. Lyoo IK, Kim MJ, Stoll AL, Demopulos CM, Parow AM, Dager SR, Friedman SD, Dunner DL, Renshaw PF. Frontal lobe gray matter density decreases in bipolar I disorder. Biological Psychiatry 2004. 55:648-51. 125. Babb SM, Ke Y, Lange N, Kaufman, MJ, Renshaw PF, Cohen BM. Oral choline increases choline metabolites in human brain. Psychiatry Research: Neuroimaging Psychiatry Research 2004: 130: 1-9 126. Naeser MA, Martin PI, Baker EH, Hodge SM, Sczerzenie SE, Nicholas M, Palumbo CL, Goodglass H, Wingfield A, Samaraweera R., Harris G, Baird A, Renshaw PF, Yurgelun-Todd DA. Overt propositional speech in chronic non-fluent aphasia studied with the dynamic susceptibility contrast fMRI method. Neuroimage. 2004; 22: 29-41. 127. Dager SR, Friedman SD, Parow AM, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF. Brain metabolic alterations in medication-free bipolar patients. Archives of General Psychiatry. 2004. 61:450-58. 128. Ehrlich S, Noam GG, Lyoo IK, Kwon BJ, Clark MA, Renshaw PF. White matter hyperintensities and their associations with suicidality in pyschiatrically hospitalized children and adoloscents. J Am Acad Child Adolescent Psychiatry. 2004; 43: 770-76. 129. Modica-Napolitano JS, Renshaw PF. Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunctional hypothesis in depression and bipolar disorder. Biological Psychiatry. 2004; 55: 273-77. 130. Ke Y, Streeter CC, Nassar LE, Sarid-Segal O, Hennen J, Yurgelun-Todd DA, Awad LA, Rendall MJ, Gruber SA, Nason A, Mudrick MJ, Blank SR, Meyer AA, Knapp C, Ciraulo DA, Renshaw PF. Frontal lobe GABA levels in cocaine dependence: a two-dimensional, J-resolved MRS study. Psychiatry Research 2004; 130: 283-93. 131. Friedman SD, Dager SR, Parow A, Hirashima F, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biological Psychiatry 2004; 56: 340-48. 132. Silveri MM, Pollack MH, Diaz CI, Nassar LE, Mendelson JH, Yurgelun-Todd DA, Renshaw PF, Kaufman MJ. Cerebral phosphorus metabolite and transverse relaxation time abnormalities in heroin- dependent subjects at onset of methadone maintenance treatment. Psychiatry Research 2004,131; 217-26. 26
  27. 27. Curriculum Vitae Perry Franklin Renshaw 133. Hirashima F, Parow AM, Satoll AL, Demopulos CM, Damico KE, Rohan ML, Eskesen JG, Zuo CS, Cohen BM, Renshaw PF. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am. Journal of Psychiatry 2004; 161: 1922-24. 134. Ahn KH, Lyoo IK, Lee HK, Song IC, Oh JS, Hwang J, Kwon J, Kim MJ, Kim M, Renshaw PF. White matter hyperintensities in subjects with bipolar disorder. Psychiatry & Clinical Neurosciences 2004; 58: 516-21. 135. Silveri MM, Anderson CM, McNeil JF, Diaz CI, Lukas SE, Mendelson JH, Renshaw PF, Kaufman MJ. Oral methylphenidate challenge selectively decreases putaminal T2 in healthy subjects. Drug Alcohol Dependence 2004; 76: 173-80. 136. Frederick BD, Lyoo IK, Satlin A, Ahn KH, Kim MJ, Yurgelun-Todd DA, Cohen BM, Renshaw PF. In vivo proton magnetic reasonance spectroscopy of the temporal lobe in Alzheimer’s disease. Prog Neuropsychopharmacol Biological Psychiatry. 2004; 28: 1313-22. 137. Anderson CM, Kaufman MJ, Lowen SB, Rohan M, Renshaw PF, Teicher MH. Brain T2 relaxation times correlate with regional cerebral blood volume. Magnetic Resonance Materials in Psysics, Biology & Medicine. 2004; MAGMA 12: 2004. 138. Lyoo IK, Streeter CC, Ahn KH, Lee HK, Pollack MH, Silveri MM, Nassar L, Levin JM, Sarid-Segal O, Ciraulo DA, Renshaw PF Kaufman MJ. White Matter hyperintensities in subjects with cocaine and opiate dependence and healthy comparison subjects. Psychiatry Res 2004; 131: 135-45. 139. Shiffer F, Mottaghy FM, Pandey Vimal RL, Renshaw PF, Cowan R, Pascual-Leone A, Teicher M, Valente E, Rohan M. Lateral visual field stimulation reveals extrastriate cortical activation in the contralateral hemisphere: an fMRI study. Psychiatry Res 2004; 131: 1-9. 140. Moeller FG, Sateinberg JL, Dougherty DM, Narayana PA, Kramer LA, Renshaw PF. Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl) 2004; 177: 185-94. 141. Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA. Amygdala and hippocampus volumes in pediatric major depression. Biological Psychiatry 2005; 57: 21-26. 142. Yildiz A, Moore, CM, Sachs GS, Demopulos CM, Tunca Z, Erbayraktar Z, Renshaw PR. Lithium induced alterations in nucleoside triphosphate levels in human brain: A proton decoupled 31P magnetic resonance spectroscopy study. Psychiatry Research: Neuroimaging (accepted for publication) Reviews and Chapters: 143. Farber SA, Slack BE, DeMicheli E, Wurtman RJ, Nitsch RM, Growdon JH, Cohen BM, Stoll AL, Renshaw PF. Choline metabolism, membrane phospholipids, and Alzheimer’s disease. In: Giacobini E, Becker R, eds. Alzheimer’s Disease: Therapeutic Strategies. Cambridge: Birkhauser; 1994; 247-51. 144. Renshaw PF, Sachs GS, Gonzalez RG. Measurement of brain lithium levels by lithium (7Li) MRS. In: Nasrallah HA, Pettegrew JW, eds. Magnetic Resonance Spectroscopy in Psychiatric Brain Disorders. Washington: American Psychiatric Press. 1994. 145. Rauch SL, Renshaw PF. Clinical neuroimaging in psychiatry. Harvard Review of Psychiatry. 1995; 2(6): 297-312. 27
  28. 28. Curriculum Vitae Perry Franklin Renshaw 146. Levin JM, Ross MH, Renshaw PF. Clinical applications of functional MRI in neuropsychiatry. Journal of Neuropsychiatry & Clinical Neurosciences. 1995; 7(4): 511-22. 147. Kaufman MJ, Levin JM, Christensen JD, Renshaw PF. Magnetic resonance studies of substance abuse. Seminars in Clinical Neuropsychiatry. 1996; 1: 61-75. 148. Yurgelun-Todd DA, Kinney DK, Sherwood AR, Renshaw PF. Magnetic resonance studies of schizophrenia. Seminars in Clinical Neuropsychiatry. 1996; 1: 07-49. 149. Lukas SE, Renshaw PF. Cocaine and other drugs of abuse: Effects on brain function. In: Higgins ST, Katz JL, eds. Cocaine abuse research: Pharmacology, behavior, and clinical applications. San Diego: Academic Press; 1996. 150. Levin JM, Ross MH, Harris G, Renshaw PF. Applications of dynamic susceptibility contrast magnetic resonance imaging in Neuropsychiatry. Neuroimage. 1996; 4(3 Pt 3): S147-62. 151. Moore CM, Renshaw PF. Magnetic resonance spectroscopy studies of affective disorders. In: Krishnan KRR, Doraiswamy PM, eds. Brain imaging in clinical psychiatry. New York: Marcel Decker; 1997; 185-214. 152. Lafer B, Renshaw PF, Sachs GS. Major depression and the basal ganglia. In: Miguel EC, Rauch SL, Leckman JF, eds. Psychiatric Clinics of North America. Vol. 20. Philadelphia: W.B. Saunders Company; 1997; 885-96. 153. Renshaw PF, Levin JM, Kaufman MJ, Ross MH, Lewis RF, Harris GJ. Dynamic susceptibility contrast magnetic resonance imaging in neuropsychiatry: present utility and future promise. European Radiology. 1997; 7(Suppl 5):216-21. 154. LaFrance ND, Parker JR, Smith MD, McGhan WF, Renshaw PF, Harris GJ, Weaver M. Dynamic susceptibility contrast MR imaging for the evaluation of probable Alzheimer disease: a cost-effectiveness analysis. Academic Radiology.1998;5(Suppl 1):S231-3; discussion S234- 5. 155. Renshaw PF, Rauch SL. Neuroimaging in clinical psychiatry. In: Nichoii AMJ, ed. The Harvard Guide to Psychiatry. Cambridge. Cambridge: Harvard University Press.1999; 84-100. 156. Yurgelun-Todd DA, Renshaw PF. Applications of functional MR imaging to research in psychiatry. Neuroimaging Clinics of North America. 1999; 9(2): 295-308. 157. Moore CM, Frederick BB, Renshaw PF. Brain biochemistry using magnetic resonance spectroscopy: relevance to psychiatric illness in the elderly. Journal of Geriatric Psychiatry & Neurology. 1999; 12(3): 107-17. 158. Karson CN, Renshaw PF. Principles of neuroimaging: Magnetic resonance techniques. In: Sadock BI, Sadock VA, eds. Comprehensive textbook of psychiatry, Seventh edition. New York: Lippincott, Williams and Wilkins; 2000;162-171. 159. Frederick B, Moore CM, Renshaw PF. Magnetic resonance spectroscopy in dementia. In: O’Brien JT, ed. Dementia. London: Chapman and Hall; 2000; 131-149. 160. Renshaw PF, Frederick B, Maas LC. Fundamentals of magnetic resonance. In: Kaufman MC, ed. Brain imaging in substance abuse. Tutonic: Humana, Press; 2000; 47-76. 28
  29. 29. Curriculum Vitae Perry Franklin Renshaw 161. Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM. Neuroimaging in bipolar disorder: what have we learned? [erratum appears in Biol Psychiatry 2001 Jan 1;49(1):80.]. Biological Psychiatry. 2000; 48(6): 505-17. 162. Yurgelun-Todd DA, Renshaw PF. MRS in childhood psychiatric disorders. In: Ernst, Rumsey, eds. Functional neuroimaging in child psychiatry. Cambridge: Cambridge University Press; 2000; 59-76. 163. Henry ME, Frederick B, Moore CM, Stoddard E, Renshaw PF. Magnetic resonance spectroscopy in psychiatric illness. Psychiatric Neuroimaging Research. 2000; 291-333. 164.Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. American Journal of Geriatric Psychiatry. 2002; 10: 81-8. 165. Renshaw PF, Parow AM. Psychiatric disease. In: Atlas S, ed. Magnetic Resonance Imaging of the Brain and Spine: Third Edition. Philadelphia: LWW 2002; 1993-2019. 166. Iosifescu DV, Renshaw PF. 31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: towards a bioenergetic mechanism in depression? Harvard Review of Psychiatry 2003; 11: 01-13. 167. Breeze JL, Hesdorffer DC, Hong X, Frazier JA,, Renshaw PF. Clinical significance of brain white matter hyperintensities in young adults with psychiatric illness. Harvard Review of Psychiatry 2003; 5: 269-83. 168.Perlis RH, Iosifescu DV, Renshaw PF. Biological predictors of treatment response in affective illness. Psychiatry Clinical North America. 2003; 26: 323-44. 169.Bolo N, Renshaw PF. Magnetic Resonance Spectroscopy. Neuroimaging for Clinical Practice.2004; 5: 105-15. Editorials 170. Cohen BM, Renshaw PF, Yurgelum-Todd DA. Imaging the mind: magnetic resonance spectroscopy and functional brain imaging. American Journal of Psychiatry. 1995; 152(5): 655-58. 171.Renshaw PF, Cohen BM. Functional brain imaging in the elderly. Journal of Nuclear Medicine. 1993; 34(7): 1101-102. Letters 172. Renshaw PF. Lithium, metal ions, and choline. Biological Psychiatry. 1987; 22(5):660-61. 173. Renshaw PF, Ford HE, Brotman AW. Possible synergistic anticonvulsant effect of propranolol and carbamazepine. American Journal of Psychiatry. 1990; 147(12): 1687-88. 174.Breiter HC, Filipek PA, Kennedy DN, Baer L, Pitcher DA, Olivares MJ, Renshaw PF, Caviness VS, Jr. Retrocallosal white matter abnormalities in patients with obsessive-compulsive disorder. Archives of General Psychiatry. 1994; 51(8):663-64. 29
  30. 30. Curriculum Vitae Perry Franklin Renshaw 175.Lyoo IK, Mino I, Renshaw PF, Lee HK. White matter hyperintensities. Journal of the American Academy of Child & Adolescent Psychiatry. 1995; 34(7): 833-34. Patents and Patent Applications: Patents 1. Maas LC, Frederick B, Renshaw PF. Decoupled automated rotational and translational registration for functional MRI time series data: the DART registration algorithm. U.S. Patent 5,850,486, 12/1998. 2. Frederick B, Wald L, Renshaw PF. Phased array echo-planer imaging system for fMRI. U.S. Patent 6,104,943, 8/2000. 3. Renshaw PF, Lukas SE. Cytidine-containing and cytosine-containing compounds as a treatment for stimulant exposure. U.S. Patent 5,958,896, 9/99; CIP 6,103,703, 8/2000. (Applications pending for use in depression, alcohol abuse/dependence, and ADHD.) 4. Renshaw PF, Lukas SE. Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure. U.S. Patent 6,103,703. 8/2000 5. Renshaw PF. Treatment of mental conditions including depression. U.S. Patent 6,258,794, 10/2000. 6. Renshaw PF. Method and apparatus for detecting mental illness. U.S. Patent 6 ,400,978. 7/2003 7. Renshaw PF, Parow AM, Rohan M. Magnetic field stimulation techniques. U.S. Patent 6,572.528. 7/2003 8. Ke Y, Renshaw PF, Cohen BM. Two-dimensional MR spectroscopy techniques. U.S. Patent 6,617,169. 9/2003 9. Renshaw PF, Cowan RL, Frederick B. Method for assessing cortical response to blue light U.S. Patent 6,630.127. 2003 Patents Pending 10. Ke Y, Renshaw PF, Lowen SB. Exponential decay modeling in spectroscopy. 11. Anderson CM, Maas LC, Renshaw PF, Teicher MH. Methods for diagnosis and assessment of attention deficit hyperactivity disorder using high speed magnetic resonance imaging. 12. Teicher MH, Anderson CM, Mass LC, Renshaw, PF, Lowen SB. Method for providing Optimal Drug Dosage. 13. Renshaw PF. Purinergic antagonists for treating depression. 14. Renshaw PF. Compounds for the treatment of psychiatric or substance abuse disorders. 15. Cowan R, Renshaw PF, Frederick deB, Lukas S. Magnetic resonance with stimulation. 16. Rohan ML, Parow A, Renshaw PF. Magnetic field stimulation techniques. 30

×